{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T10:24:53Z","timestamp":1780050293463,"version":"3.53.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T00:00:00Z","timestamp":1733184000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004375","name":"Tel Aviv University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004375","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Pediatr"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Onasemnogene abeparvovec (OA) is a novel gene replacement therapy for patients with spinal muscular atrophy (SMA). This study provides real-world respiratory data for pediatric SMA patients receiving OA who were assessed before and one year after treatment in a multicenter cohort study conducted from 2019 to 2021. Twenty-five OA-treated SMA patients (23 with type 1 and 2 with type 2; median age at treatment 6.1\u00a0months, with a range of 0.36\u201323\u00a0months) were included. Sixteen were treatment-na\u00efve, and nine had received various prior treatments. Two patients died due to respiratory failure during the study period. Of the remaining 23 patients, four were put on non-invasive ventilation (NIV), bringing ventilated patients to a total of ten during the post-treatment year. Three patients required permanent NIV support, while 13 did not require any respiratory support. Ventilation time decreased from 14.3 to 11.1\u00a0hours per day, and respiratory hospitalizations decreased by 26% (from 0.76 to 0.57 per life year). Fifteen of the 23 patients maintained full oral nutrition at study closure compared to 20 of the 25 at study initiation. This real-world data analysis demonstrates that OA may improve respiratory outcomes in SMA patients. Importantly, compounding factors, such as age at treatment initiation, treatment combinations, and natural history, may influence the respiratory course, thus highlighting the need for standardized long-term management.<jats:table-wrap>\n              <jats:table>\n                <jats:tbody>\n                  <jats:tr>\n                    <jats:td colspan=\"2\">\n                      <jats:bold>What is Known:<\/jats:bold>\n                      <jats:italic>\u2022 Respiratory failure is a leading cause of mortality in untreated spinal muscular atrophy type 1 patients.<\/jats:italic>\n                      <jats:italic>\u2022 Onasemnogene abeparvovec (OA) improves neurological outcomes, but real-world respiratory data are limited.<\/jats:italic>\n                    <\/jats:td>\n                  <\/jats:tr>\n                  <jats:tr>\n                    <jats:td colspan=\"2\">\n                      <jats:bold>What is New:<\/jats:bold>\n                      <jats:italic>\u2022 Our real-world analysis suggests OA may improve respiratory outcomes.<\/jats:italic>\n                      <jats:italic>\u2022 Age at treatment and treatment combinations may also influence respiratory trajectory.<\/jats:italic>\n                    <\/jats:td>\n                  <\/jats:tr>\n                <\/jats:tbody>\n              <\/jats:table>\n            <\/jats:table-wrap>\n          <\/jats:p>","DOI":"10.1007\/s00431-024-05886-9","type":"journal-article","created":{"date-parts":[[2024,12,3]],"date-time":"2024-12-03T05:30:57Z","timestamp":1733203857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Respiratory outcomes of onasemnogene abeparvovec treatment for spinal muscular atrophy: national real-world cohort study"],"prefix":"10.1007","volume":"184","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7498-7085","authenticated-orcid":false,"given":"Moran","family":"Lavie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1875-0902","authenticated-orcid":false,"given":"Mika","family":"Rochman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keren","family":"Armoni Domany","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6259-405X","authenticated-orcid":false,"given":"Inbal","family":"Golan Tripto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moria","family":"Be\u2019er","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omri","family":"Besor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liora","family":"Sagi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Aharoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Ginsberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2916-7600","authenticated-orcid":false,"given":"Iris","family":"Noyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Levine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,3]]},"reference":[{"issue":"8","key":"5886_CR1","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/archneurol.2011.74","volume":"68","author":"SJ Kolb","year":"2011","unstructured":"Kolb SJ, Kissel JT (2011) Spinal muscular atrophy: a timely review. Arch Neurol 68(8):979\u2013984","journal-title":"Arch Neurol"},{"key":"5886_CR2","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1002\/ana.25101","volume":"82","author":"SJ Kolb","year":"2017","unstructured":"Kolb SJ, Coffey CS, Yankey JW et al (2017) Natural history of infantile-onset spinal muscular atrophy. Ann Neurol 82:883\u2013891. https:\/\/doi.org\/10.1002\/ana.25101","journal-title":"Ann Neurol"},{"key":"5886_CR3","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.nmd.2016.10.002","volume":"26","author":"RD Sanctis","year":"2016","unstructured":"Sanctis RD, Coratti G, Pasternak A et al (2016) Developmental milestones in type I spinal muscular atrophy. Neuromuscul Disord 26:754\u2013759. https:\/\/doi.org\/10.1016\/j.nmd.2016.10.002","journal-title":"Neuromuscul Disord"},{"key":"5886_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1177\/088307389400900321","volume":"9","author":"FJ Samaha","year":"1994","unstructured":"Samaha FJ, Buncher CR, Russman BS et al (1994) Pulmonary function in spinal muscular atrophy. J Child Neurol 9:326\u2013329. https:\/\/doi.org\/10.1177\/088307389400900321","journal-title":"J Child Neurol"},{"key":"5886_CR5","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/S1474-4422(21)00001-6","volume":"20","author":"JW Day","year":"2021","unstructured":"Day JW, Finkel RS, Chiriboga CA et al (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy in patients with two copies of SMN2 (STR1VE): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20:284\u2013293. https:\/\/doi.org\/10.1016\/S1474-4422(21)00001-6","journal-title":"Lancet Neurol"},{"key":"5886_CR6","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1016\/S1474-4422(21)00251-9","volume":"20","author":"E Mercuri","year":"2021","unstructured":"Mercuri E, Muntoni F, Baranello G et al (2021) Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Lancet Neurol 20:832\u2013841. https:\/\/doi.org\/10.1016\/S1474-4422(21)00251-9","journal-title":"Lancet Neurol"},{"key":"5886_CR7","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1001\/jamaneurol.2021.1272","volume":"78","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Lehman KJ et al (2021) Five-year extension results of the phase 1 START trial of Onasemnogene Abeparvovec in spinal muscular atrophy. JAMA Neurol 78:834. https:\/\/doi.org\/10.1001\/jamaneurol.2021.1272","journal-title":"JAMA Neurol"},{"key":"5886_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ejpn.2024.06.004","volume":"51","author":"D Giess","year":"2024","unstructured":"Giess D, Erdos J, Wild C (2024) An updated systematic review on spinal muscular atrophy patients treated with nusinersen, onasemnogene abeparvovec (at least 24 months), risdiplam (at least 12 months) or combination therapies. Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc 51:84\u201392. https:\/\/doi.org\/10.1016\/j.ejpn.2024.06.004","journal-title":"Eur J Paediatr Neurol EJPN Off J Eur Paediatr Neurol Soc"},{"key":"5886_CR9","doi-asserted-by":"publisher","first-page":"3017","DOI":"10.1016\/S0140-6736(16)31408-8","volume":"388","author":"RS Finkel","year":"2016","unstructured":"Finkel RS, Chiriboga CA, Vajsar J et al (2016) Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet 388:3017\u20133026. https:\/\/doi.org\/10.1016\/S0140-6736(16)31408-8","journal-title":"Lancet"},{"key":"5886_CR10","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1002\/ppul.26448","volume":"58","author":"C Leon-Astudillo","year":"2023","unstructured":"Leon-Astudillo C, Okorie CUA, McCown MY et al (2023) ATS core curriculum 2022. Pediatric pulmonary medicine: updates in pediatric neuromuscular disease. Pediatr Pulmonol 58:1866\u20131874. https:\/\/doi.org\/10.1002\/ppul.26448","journal-title":"Pediatr Pulmonol"},{"key":"5886_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/ppul.25135","volume":"56","author":"GR Paul","year":"2021","unstructured":"Paul GR, Gushue C, Kotha K, Shell R (2021) The respiratory impact of novel therapies for spinal muscular atrophy. Pediatr Pulmonol 56:721\u2013728. https:\/\/doi.org\/10.1002\/ppul.25135","journal-title":"Pediatr Pulmonol"},{"key":"5886_CR12","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/ana.24864","volume":"81","author":"MA Farrar","year":"2017","unstructured":"Farrar MA, Park SB, Vucic S et al (2017) Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol 81:355\u2013368. https:\/\/doi.org\/10.1002\/ana.24864","journal-title":"Ann Neurol"},{"key":"5886_CR13","unstructured":"Package Insert - ZOLGENSMA - ZOLGENSMA\u00ae (onasemnogene abeparvovec-xioi) suspension, for intravenous infusion.\u00a0https:\/\/www.fda.gov\/media\/126109\/download"},{"key":"5886_CR14","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12883-023-03133-6","volume":"23","author":"GM Stettner","year":"2023","unstructured":"Stettner GM, Hasselmann O, Tscherter A et al (2023) Treatment of spinal muscular atrophy with Onasemnogene Abeparvovec in Switzerland: a prospective observational case series study. BMC Neurol 23:88. https:\/\/doi.org\/10.1186\/s12883-023-03133-6","journal-title":"BMC Neurol"},{"key":"5886_CR15","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.3390\/children9081207","volume":"9","author":"P Panagiotou","year":"2022","unstructured":"Panagiotou P, Kanaka-Gantenbein C, Kaditis AG (2022) Changes in ventilatory support requirements of spinal muscular atrophy (SMA) patients post gene-based therapies. Children 9:1207. https:\/\/doi.org\/10.3390\/children9081207","journal-title":"Children"},{"key":"5886_CR16","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1002\/ppul.26285","volume":"58","author":"A AlNaimi","year":"2023","unstructured":"AlNaimi A, Hamad SG, Mohamed RBA et al (2023) A breakthrough effect of gene replacement therapy on respiratory outcomes in children with spinal muscular atrophy. Pediatr Pulmonol 58:1004\u20131011. https:\/\/doi.org\/10.1002\/ppul.26285","journal-title":"Pediatr Pulmonol"},{"key":"5886_CR17","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ppul.24203","volume":"54","author":"S Al-Zaidy","year":"2019","unstructured":"Al-Zaidy S, Pickard AS, Kotha K et al (2019) Health outcomes in spinal muscular atrophy type 1 following AVXS-101 gene replacement therapy. Pediatr Pulmonol 54:179\u2013185. https:\/\/doi.org\/10.1002\/ppul.24203","journal-title":"Pediatr Pulmonol"},{"key":"5886_CR18","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S2352-4642(21)00287-X","volume":"6","author":"C Wei\u00df","year":"2022","unstructured":"Wei\u00df C, Ziegler A, Becker L-L et al (2022) Gene replacement therapy with onasemnogene abeparvovec in children with spinal muscular atrophy aged 24 months or younger and bodyweight up to 15 kg: an observational cohort study. Lancet Child Adolesc Health 6:17\u201327. https:\/\/doi.org\/10.1016\/S2352-4642(21)00287-X","journal-title":"Lancet Child Adolesc Health"},{"key":"5886_CR19","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3233\/JND-221531","volume":"10","author":"KE McGrattan","year":"2023","unstructured":"McGrattan KE, Shell RD, Hurst-Davis R et al (2023) Patients with spinal muscular atrophy type 1 achieve and maintain bulbar function following Onasemnogene Abeparvovec treatment1. J Neuromuscul Dis 10:531\u2013540. https:\/\/doi.org\/10.3233\/JND-221531","journal-title":"J Neuromuscul Dis"},{"key":"5886_CR20","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.sleep.2023.09.019","volume":"111","author":"J Chiang","year":"2023","unstructured":"Chiang J, Xiao L, Nigro E et al (2023) Sleep disordered breathing in infants identified through newborn screening with spinal muscular atrophy. Sleep Med 111:161\u2013169. https:\/\/doi.org\/10.1016\/j.sleep.2023.09.019","journal-title":"Sleep Med"},{"key":"5886_CR21","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/ppul.25795","volume":"57","author":"M Lavie","year":"2022","unstructured":"Lavie M, Rochman M, Sagi L et al (2022) Nonrespiratory complications of nusinersen-treated spinal muscular atrophy type 1 patients. Pediatr Pulmonol 57:686\u2013694. https:\/\/doi.org\/10.1002\/ppul.25795","journal-title":"Pediatr Pulmonol"}],"container-title":["European Journal of Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00431-024-05886-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00431-024-05886-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T03:44:09Z","timestamp":1737690249000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00431-024-05886-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,3]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["5886"],"URL":"https:\/\/doi.org\/10.1007\/s00431-024-05886-9","relation":{},"ISSN":["1432-1076"],"issn-type":[{"value":"1432-1076","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,3]]},"assertion":[{"value":"8 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 November 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"58"}}